Discuss Early Results of the DIAN Trial at CBI's 6th Annual Alzheimer's Drug Development Summit

WOBURN, Mass., Aug. 21, 2012 /PRNewswire/ -- CBI recently added John C. Morris M.D., a Friedman Distinguished Professor of Neurology and Director at Knight Research Center of Washington University School of Medicine, to the prestigious speaker roster for CBI's 6th Annual Alzheimer's Drug Development Summit in Philadelphia.

This December 11-12, attendees come together during the session: Future Perspective from the Dominantly Inherited Alzheimer Network (DIAN) (http://www.cbinet.com/conference/workshop/26087/pc12188) to discuss the early results from the trial as well as review key highlights and information:

• Analyze the importance of the DIAN trial to Alzheimer's clinical trials
• Discuss the therapies being evaluated in the DIAN trial and study design
• Understand the initial results of the DIAN clinical trial and forward goals

With a strong agenda filled with expert speakers reflecting on recent clinical trial implications and current research on translational and preventative treatments for Alzheimer's, CBI's 6th Annual Alzheimer's Drug Development Summit offers industry leaders an educational platform to continue the dialogue of research findings and continue to advance towards the prevention and treatment of Alzheimer's disease.

CBI, an Advanstar company, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators.

Contact: Kristina Weljkovic
Phone number: 339-298-2285
Email address: [email protected]

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.  

SOURCE CBI